{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T06:57:47Z","timestamp":1774767467358,"version":"3.50.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"DOI":"10.1007\/s11899-026-00770-9","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:11:03Z","timestamp":1768471863000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Understanding Triple Negative Myeloproliferative Neoplasms and Identifying Molecular Drivers"],"prefix":"10.1007","volume":"21","author":[{"given":"Valentina","family":"Boldrini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6241-1206","authenticated-orcid":false,"given":"Giuseppe G.","family":"Loscocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"issue":"3","key":"770_CR1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3322\/caac.20009","volume":"59","author":"AM Vannucchi","year":"2009","unstructured":"Vannucchi AM, Guglielmelli P, Tefferi A. Advances in Understanding and management of myeloproliferative neoplasms. Cancer J Clin. 2009;59(3):171\u201391.","journal-title":"Cancer J Clin"},{"issue":"11","key":"770_CR2","first-page":"1200","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood J Am Soc Hematol. 2022;140(11):1200\u201328.","journal-title":"Blood J Am Soc Hematol"},{"key":"770_CR3","unstructured":"Khoury JD et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms, Leukemia, vol. 36, no. 7, pp. 1703\u20131719, 2022."},{"issue":"4","key":"770_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/ejh.12256","volume":"92","author":"O Moulard","year":"2014","unstructured":"Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia Vera in the E uropean U Nion. Eur J Haematol. 2014;92(4):289\u201397.","journal-title":"Eur J Haematol"},{"issue":"16","key":"770_CR5","first-page":"2507","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood, The Journal of the American Society of Hematology. 2014;124(16):2507\u201313.","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"5","key":"770_CR6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/ajh.26857","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(5):801\u201321.","journal-title":"Am J Hematol"},{"issue":"1","key":"770_CR7","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1016\/S2352-3026(23)00305-8","volume":"11","author":"N Kr\u00f6ger","year":"2024","unstructured":"Kr\u00f6ger N, et al. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT\/ELN International Working Group. Lancet Haematol. 2024;11(1):e62\u201374.","journal-title":"Lancet Haematol"},{"key":"770_CR8","doi-asserted-by":"crossref","unstructured":"Rampal R et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms, Proceedings of the National Academy of Sciences, vol. 111, no. 50, pp. E5401-E5410, 2014.","DOI":"10.1073\/pnas.1407792111"},{"issue":"9464","key":"770_CR9","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054\u201361.","journal-title":"Lancet"},{"issue":"4","key":"770_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387\u201397.","journal-title":"Cancer Cell"},{"issue":"17","key":"770_CR11","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779\u201390.","journal-title":"N Engl J Med"},{"key":"770_CR12","doi-asserted-by":"crossref","unstructured":"James C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera, Nature, vol. 434, no. 7037, pp. 1144\u20131148, 2005.","DOI":"10.1038\/nature03546"},{"issue":"8","key":"770_CR13","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/ajh.22063","volume":"86","author":"LM Scott","year":"2011","unstructured":"Scott LM. The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol. 2011;86(8):668\u201376.","journal-title":"Am J Hematol"},{"issue":"1","key":"770_CR14","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1182\/asheducation-2014.1.268","volume":"2014","author":"E Chen","year":"2014","unstructured":"Chen E, Mullally A. How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms? Hematology. 2014;2014(1):268\u201376.","journal-title":"Hematology"},{"issue":"25","key":"770_CR15","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379\u201390. https:\/\/doi.org\/10.1056\/NEJMoa1311347.","journal-title":"N Engl J Med"},{"issue":"25","key":"770_CR16","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391\u2013405.","journal-title":"N Engl J Med"},{"issue":"7","key":"770_CR17","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.","journal-title":"PLoS Med"},{"key":"770_CR18","doi-asserted-by":"crossref","unstructured":"Pardanani AD et al. MPL 515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients, Blood, vol. 108, no. 10, pp. 3472\u20133476, 2006.","DOI":"10.1182\/blood-2006-04-018879"},{"issue":"5","key":"770_CR19","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1182\/blood-2005-06-2600","volume":"107","author":"J Staerk","year":"2006","unstructured":"Staerk J, Lacout C, Sato T, Smith SO, Vainchenker W, Constantinescu SN. An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood. 2006;107(5):1864\u201371.","journal-title":"Blood"},{"issue":"1","key":"770_CR20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jmoldx.2016.08.006","volume":"19","author":"F Usseglio","year":"2017","unstructured":"Usseglio F, Beaufils N, Calleja A, Raynaud S, Gabert J. Detection of CALR and MPL mutations in low allelic burden JAK2 V617F essential thrombocythemia. J Mol Diagn. 2017;19(1):92\u20138.","journal-title":"J Mol Diagn"},{"key":"770_CR21","doi-asserted-by":"crossref","unstructured":"McGaffin G, Harper K, Stirling D, McLintock L. JAK2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort. Br J Haematol, 167, 2, 2014.","DOI":"10.1111\/bjh.12969"},{"key":"770_CR22","doi-asserted-by":"crossref","unstructured":"Thompson ER et al. Clonal independence of JAK2 and CALR or MPL mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing, Haematologica, vol. 106, no. 1, p. 313, 2020.","DOI":"10.3324\/haematol.2020.260448"},{"key":"770_CR23","doi-asserted-by":"crossref","unstructured":"Tefferi A, Vannucchi AM. Genetic risk assessment in myeloproliferative neoplasms, in Mayo Clinic Proceedings, 2017, vol. 92, no. 8: Elsevier, pp. 1283\u20131290.","DOI":"10.1016\/j.mayocp.2017.06.002"},{"issue":"3","key":"770_CR24","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ajh.24978","volume":"93","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, et al. Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. Am J Hematol. 2018;93(3):348\u201355.","journal-title":"Am J Hematol"},{"key":"770_CR25","unstructured":"Gangat N, Reichard KK, Orazi A, Viswanatha DS, Hanson CA, Tefferi A. Treatment-relevant misdiagnosis of autoimmune myelofibrosis. Haematologica, 2020."},{"key":"770_CR26","doi-asserted-by":"crossref","unstructured":"Tefferi A et al. Essential thrombocythemia: A review, Jama, 2025.","DOI":"10.1001\/jama.2024.25349"},{"issue":"10","key":"770_CR27","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1007\/s00277-019-03766-z","volume":"98","author":"A Alvarez-Larr\u00e1n","year":"2019","unstructured":"Alvarez-Larr\u00e1n A, et al. Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis. Ann Hematol. 2019;98(10):2319\u201328.","journal-title":"Ann Hematol"},{"issue":"3","key":"770_CR28","first-page":"325","volume":"127","author":"JD Milosevic Feenstra","year":"2016","unstructured":"Milosevic Feenstra JD, et al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood J Am Soc Hematol. 2016;127(3):325\u201332.","journal-title":"Blood J Am Soc Hematol"},{"issue":"3","key":"770_CR29","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","volume":"127","author":"X Cabagnols","year":"2016","unstructured":"Cabagnols X, et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood. 2016;127(3):333\u201342.","journal-title":"Blood"},{"issue":"12","key":"770_CR30","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1038\/leu.2015.249","volume":"29","author":"S Swierczek","year":"2015","unstructured":"Swierczek S, Lima LT, Tashi T, Kim SJ, Gregg XT, Prchal JT. Presence of polyclonal hematopoiesis in females with Ph-negative myeloproliferative neoplasms. Leukemia. 2015;29(12):2432\u20134.","journal-title":"Leukemia"},{"key":"770_CR31","doi-asserted-by":"crossref","unstructured":"Forte D, et al. Distinct profile of CD34\u2009+\u2009cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease. Journal of Experimental & Clinical Cancer Research. 2021;40(1):49.","DOI":"10.1186\/s13046-020-01776-8"},{"issue":"4","key":"770_CR32","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1182\/bloodadvances.2020003172","volume":"5","author":"S Alimam","year":"2021","unstructured":"Alimam S, et al. Patients with triple-negative, JAK2 V617F-and CALR-mutated essential thrombocythemia share a unique gene expression signature. Blood Adv. 2021;5(4):1059\u201368.","journal-title":"Blood Adv"},{"issue":"4","key":"770_CR33","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","volume":"36","author":"P Guglielmelli","year":"2017","unstructured":"Guglielmelli P, et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2017;36(4):310\u20138.","journal-title":"J Clin Oncol"},{"issue":"17","key":"770_CR34","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","volume":"36","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, et al. MIPSS70\u2009+\u2009Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. Journal of Clinical Oncology. 2018;36(17):1769.","journal-title":"Journal of Clinical Oncology"},{"key":"770_CR35","doi-asserted-by":"crossref","unstructured":"Tefferi A et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons, Leukemia, vol. 28, no. 7, pp. 1472\u20131477, 2014.","DOI":"10.1038\/leu.2014.3"},{"issue":"23","key":"770_CR36","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1182\/blood.V126.23.4091.4091","volume":"126","author":"G Rotunno","year":"2015","unstructured":"Rotunno G, et al. Mutational landscape of patients with myelofibrosis that do not harbor mutations in JAK2, MPL and Calreticulin driver genes. Blood. 2015;126(23):4091.","journal-title":"Blood"},{"issue":"3","key":"770_CR37","doi-asserted-by":"publisher","first-page":"100016","DOI":"10.1016\/j.modpat.2022.100016","volume":"36","author":"YA Al-Ghamdi","year":"2023","unstructured":"Al-Ghamdi YA, et al. Triple-negative primary myelofibrosis: a bone marrow pathology group study. Mod Pathol. 2023;36(3):100016.","journal-title":"Mod Pathol"},{"issue":"15","key":"770_CR38","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1182\/bloodadvances.2020002175","volume":"4","author":"G Coltro","year":"2020","unstructured":"Coltro G, et al. RAS\/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features. Blood advances. 2020;4(15):3677\u201387.","journal-title":"Blood advances"},{"key":"770_CR39","doi-asserted-by":"crossref","unstructured":"Svidnicki MCCM et al. Mutations in triple-negative patients with myeloproliferative neoplasms, Blood, vol. 134, p. 5395, 2019.","DOI":"10.1182\/blood-2019-128764"},{"key":"770_CR40","doi-asserted-by":"publisher","first-page":"637116","DOI":"10.3389\/fonc.2021.637116","volume":"11","author":"D Cattaneo","year":"2021","unstructured":"Cattaneo D, et al. Triple-negative essential thrombocythemia: clinical-pathological and molecular features. A single-center cohort study. Front Oncol. 2021;11:637116.","journal-title":"Front Oncol"},{"key":"770_CR41","doi-asserted-by":"crossref","unstructured":"Acha P et al. Diagnostic and prognostic contribution of targeted NGS in patients with triple-negative myeloproliferative neoplasms. Am J Hematol, 94, 10, pp. E264-E267, 2019.","DOI":"10.1002\/ajh.25580"},{"key":"770_CR42","doi-asserted-by":"crossref","unstructured":"Crespiatico I et al. First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis, Blood, vol. 143, no. 14, pp. 1399\u20131413, 2024.","DOI":"10.1182\/blood.2023021349"},{"issue":"4","key":"770_CR43","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/ajh.27609","volume":"100","author":"A Tefferi","year":"2025","unstructured":"Tefferi A, et al. TP53 mutations in myeloproliferative neoplasms: context-dependent evaluation of prognostic relevance. American journal of hematology. 2025;100(4):552\u201360.","journal-title":"American journal of hematology"},{"issue":"2","key":"770_CR44","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","volume":"1","author":"A Tefferi","year":"2016","unstructured":"Tefferi A, et al. Targeted deep sequencing in primary myelofibrosis. Blood Adv. 2016;1(2):105\u201311.","journal-title":"Blood Adv"},{"issue":"8","key":"770_CR45","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.3390\/cancers12082216","volume":"12","author":"M Hautin","year":"2020","unstructured":"Hautin M, Mornet C, Chauveau A, Bernard DG, Corcos L, Lippert E. Splicing anomalies in myeloproliferative neoplasms: paving the way for new therapeutic venues. Cancers. 2020;12(8):2216.","journal-title":"Cancers"},{"issue":"5","key":"770_CR46","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41375-018-0018-z","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, et al. Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. Leukemia. 2018;32(5):1189\u201399.","journal-title":"Leukemia"},{"key":"770_CR47","doi-asserted-by":"crossref","unstructured":"Tefferi A et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis, Leukemia, vol. 32, no. 7, pp. 1631\u20131642, 2018.","DOI":"10.1038\/s41375-018-0107-z"},{"issue":"1","key":"770_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41408-023-00972-x","volume":"14","author":"N Gangat","year":"2024","unstructured":"Gangat N, et al. One thousand patients with essential thrombocythemia: the Mayo clinic experience. Blood Cancer J. 2024;14(1):11.","journal-title":"Blood Cancer J"},{"issue":"7","key":"770_CR49","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.1038\/emm.2016.55","volume":"48","author":"Y Kim","year":"2016","unstructured":"Kim Y, et al. Genetic\u2013pathologic characterization of myeloproliferative neoplasms. Exp Mol Med. 2016;48(7):e247\u2013247.","journal-title":"Exp Mol Med"},{"key":"770_CR50","doi-asserted-by":"crossref","unstructured":"Loscocco GG, et al. One thousand patients with essential thrombocythemia: the Florence-CRIMM experience. Blood Cancer Journal. 2024;14(1):10.","DOI":"10.1038\/s41408-023-00968-7"},{"issue":"7","key":"770_CR51","first-page":"1062","volume":"124","author":"E Rumi","year":"2014","unstructured":"Rumi E, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood J Am Soc Hematol. 2014;124(7):1062\u20139.","journal-title":"Blood J Am Soc Hematol"},{"key":"770_CR52","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1182\/blood-2021-151978","volume":"138","author":"LE Aguirre","year":"2021","unstructured":"Aguirre LE, et al. Triple-Negative myelofibrosis: disease Features, response to treatment and outcomes. Blood. 2021;138:1494.","journal-title":"Blood"},{"issue":"4","key":"770_CR53","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/ajh.24293","volume":"91","author":"M Haider","year":"2016","unstructured":"Haider M, et al. Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients. Am J Hematol. 2016;91(4):390\u20134.","journal-title":"Am J Hematol"},{"issue":"11","key":"770_CR54","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1038\/bcj.2015.94","volume":"5","author":"T Barbui","year":"2015","unstructured":"Barbui T, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5(11):e369\u2013369.","journal-title":"Blood Cancer J"},{"key":"770_CR55","doi-asserted-by":"crossref","unstructured":"Passamonti F et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis, Leukemia, vol. 31, no. 12, pp. 2726\u20132731, 2017.","DOI":"10.1038\/leu.2017.169"},{"key":"770_CR56","first-page":"1101","volume":"4","author":"J Kiladjian","year":"2020","unstructured":"Kiladjian J, et al. Imetelstat treatment results in clinical benefits, including improved overall survival, in patients with higher-risk triple-negative myelofibrosis relapsed\/refractory to Janus kinase inhibitors (jaki). Hemasphere. 2020;4:1101.","journal-title":"Hemasphere"},{"issue":"26","key":"770_CR57","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1200\/JCO.20.02864","volume":"39","author":"J Mascarenhas","year":"2021","unstructured":"Mascarenhas J, et al. Randomized, single-blind, multicenter phase II study of two doses of imetelstat in relapsed or refractory myelofibrosis. J Clin Oncol. 2021;39(26):2881\u201392.","journal-title":"J Clin Oncol"},{"issue":"20","key":"770_CR58","first-page":"2233","volume":"133","author":"N Gagelmann","year":"2019","unstructured":"Gagelmann N, et al. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood J Am Soc Hematol. 2019;133(20):2233\u201342.","journal-title":"Blood J Am Soc Hematol"},{"issue":"4","key":"770_CR59","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.bbmt.2017.10.037","volume":"24","author":"RB Salit","year":"2018","unstructured":"Salit RB, Deeg HJ. Transplant decisions in patients with myelofibrosis: should mutations be the judge? Biol Blood Marrow Transplant. 2018;24(4):649\u201358.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"770_CR60","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/10428194.2024.2422835","volume":"66","author":"N Sharma","year":"2025","unstructured":"Sharma N, et al. When and how to transplant in myelofibrosis\u2013recent trends. Leukemia & Lymphoma. 2025;66(3):359\u201377.","journal-title":"Leukemia & Lymphoma"},{"key":"770_CR61","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ajh.27658","volume":"100","author":"GG Loscocco","year":"2025","unstructured":"Loscocco GG, Guglielmelli P. Targeted therapies in myelofibrosis: present Landscape, ongoing Studies, and future perspectives. Am J Hematol. 2025;100:30\u201350.","journal-title":"Am J Hematol"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00770-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-026-00770-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00770-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T11:02:41Z","timestamp":1768474961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-026-00770-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["770"],"URL":"https:\/\/doi.org\/10.1007\/s11899-026-00770-9","relation":{},"ISSN":["1558-822X"],"issn-type":[{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"No conflict of interest for any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}